Use of lacosamide in children: experience of a tertiary medical care center in Brazil

Background  Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Romão, Tayla Taynan, Angelim, Abraão Iuri Medeiros, Prado, Henrique Jannuzzelli Pires do, Goes, Fernanda Veiga de, Pires, Maria Elisa Paiva, Fontana, Rosiane da Silva, Pires, Lais de Carvalho, Fernandes, Alexandre Ribeiro, D'Andrea-Meira, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797266/
https://www.ncbi.nlm.nih.gov/pubmed/36577407
http://dx.doi.org/10.1055/s-0042-1758366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797266/
https://www.ncbi.nlm.nih.gov/pubmed/36577407
http://dx.doi.org/10.1055/s-0042-1758366

Ejemplares similares